Blog
RSS FeedPosted by Michael Wonder on 18 Jan 2024
New orphan drug for a sub-type of acute myeloid leukaemia: G-BA sees significant additional benefit
18 January 2024 - Since July 2023, there has been one in Germany for patients who suffer from acute myeloid leukaemia ...
Posted by Michael Wonder on 04 Dec 2023
Vosoritide in achondroplasia: indication of an additional clinical benefit for children aged two and over
1 December 2023 - Two small RCTs with children of different ages together make it possible to make one statement: the ...
Posted by Michael Wonder on 15 Nov 2023
Early benefit assessment: meaningful RCTs are also feasible in late oncological treatment lines
15 November 2023 - Two randomised controlled studies in the third and fourth lines for colorectal and breast cancer each show ...
Posted by Michael Wonder on 09 Oct 2023
Multiple sclerosis: hardly any evidence for good patient care
4 October 2023 - Even in the final report, many questions about the treatment of relapsing-remitting multiple sclerosis remain unanswered because ...
Posted by Michael Wonder on 08 Oct 2023
Clinical studies: you can see better with the second arm
6 October 2023 - In a statement to the EMA, the IQWiG emphasised that single-arm studies may be sufficient for ...
Posted by Michael Wonder on 05 Oct 2023
Orphan drug for multiple myeloma: G-BA must formally certify legally assumed additional benefit
5 October 2023 - Due to legal requirements, the Federal Joint Committee (G-BA) has completed the re-evaluation process for belantamab mafodotin ...
Posted by Michael Wonder on 19 Sep 2023
How IQWiG assesses – version 7.0 of the method paper comes into force
19 September 2023 - Fundamental revision of the cost benefit assessment and addition of the concept of application-accompanying data collection. ...
Posted by Michael Wonder on 02 Sep 2023
Lisocabtagene maraleucel in second-line B-cell lymphoma: additional benefit for certain patients
1 September 2023 - On the basis of the available data, there is a hint of a non-quantifiable added benefit ...
Posted by Michael Wonder on 17 Aug 2023
Do France, Germany, and Italy agree on the added therapeutic value of medicines?
17 August 2023 - The Health Technology Assessment of medicines is performed separately at the country level with some differences, but ...
Posted by Michael Wonder on 02 Aug 2023
Upadacitinib in active Crohn's disease: no additional benefit proven due to a lack of comparative studies
1 August 2023 - Although biologics have been used in Crohn's disease for over 20 years, there are hardly any studies ...
Posted by Michael Wonder on 25 Jul 2023
"Last hope": Eager Germans are prepared to pay for weight loss drug
25 July 2023 - Frustrated after countless failed diet and exercise attempts, 41 year old Jessica Lenth from Hamburg has ...
Posted by Michael Wonder on 06 Jul 2023
Extension of indications in drug approval: often without proof of additional benefit
6 July 2023 - In a comment in the BMJ, the head of the IQWiG Department for drug assessment advocates approval ...
Posted by Michael Wonder on 13 May 2023
Orphan drugs: early generation of evidence urgently needed
10 May 2023 - A team led by IQWiG authors, together with Rita Banzi from the Italian Mario Negri Institute, analysed ...
Posted by Michael Wonder on 17 Apr 2023
Olaparib in metastatic prostate cancer: added benefit for certain patients
17 April 2023 - Younger treatment naïve patients benefit. No relevant data were presented for previously treated patients. ...
Posted by Michael Wonder on 05 Apr 2023
Are German drug pricing regulations chasing some drug makers away, causing them to withdraw products from the market?
5 April 2023 - Germany’s pharmaceutical market is the most important one on the European continent. ...